fashion -WSS

fashion

author：focus 2025-09-30 22:05:19 - browse：55

Adobe

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing business in the United States.

Legislation proposing that blacklist, known as the BIOSECURE Act, was passed in a 40-1 bipartisan vote on Wednesday by the House Oversight and Accountability Committee. That’s an important development because until now, the House Select Committee on the Chinese Communist Party had handled the bill in the House. That panel is an ad-hoc committee created to build bipartisan consensus on China policies, but it does not have the authority to pass legislation. A Senate committee also passed the BIOSECURE Act nearly unanimously earlier this year.

With the bill out of the Oversight Committee, the goal is for the House to pass it before the July 4 recess. That would set the legislation up to be included in a year-end must-pass legislative package, possibly the National Defense Authorization Act, which Congress has passed every year for decades.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Diversity in clinical trials starts with building trust, experts say

WSS

Why rehabilitation engineers need to center patients in their research

Will the market for weight loss drugs really reach $100 billion?

J&J to emphasize cancer drugs, stop much of its vaccine research

30 years of 'Listening to Prozac'

30 years of 'Listening to Prozac'

What to do when lifesaving products contribute to climate change

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Cancer researcher Catriona Jamieson is sending tumors into space

As demand for Covid shots wanes, Moderna seeks its next success

Bird flu in milk supply is likely coming from asymptomatic cows

Hepatitis C has a cure — but many Americans still lack access to it

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Guidelines to prevent youth baseball injuries need more muscle

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Anesthesiologist group: stop taking Ozempic before surgery

The EPA's new lead rule: How one expert crunched the numbers

hotspot

Pediatric cancer treatments threatened by a new FDA policy

FDA investigates CAR

As biotech industry slumps, bioscience job market is upside down

Will the market for weight loss drugs really reach $100 billion?

Rep. Raul Ruiz on the physician shortage and more

Getting Alzheimer's drug Leqembi to patients can be a challenge

Wikipedia

knowledge

explore

hotspot